Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

L. Leslie · SciRah

Researcher profile · Semantic Scholar

L. Leslie

Share profile

L. Leslie — researcher profile on SciRah

h-index: 20
Works: 123
Citations: 3,603

Most-cited papers

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.
F. Locke, D. Miklos, C. Jacobson, M. Perales +27 more
2021New England Journal of Medicine1,192 citations Open access
Semantic Scholar
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.
C. Jacobson, J. Chavez, A. Sehgal, B. William +19 more
2021The Lancet Oncology524 citations
Semantic Scholar
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma.
J. Westin, Olalekan O. Oluwole, M. Kersten, D. Miklos +26 more
2023New England Journal of Medicine334 citations Open access
Semantic Scholar
Outcomes of COVID-19 in patients with CLL: a multicenter international experience
A. Mato, L. Roeker, N. Lamanna, J. Allan +58 more
2020Blood296 citations Open access
Semantic Scholar
Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma
N. Fowler, F. Samaniego, W. Jurczak, N. Ghosh +24 more
2021Journal of Clinical Oncology126 citations Open access
Semantic Scholar
Primary Analysis of Zuma-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)
C. Jacobson, J. Chavez, A. Sehgal, B. William +21 more
2020110 citations Open access
Semantic Scholar
Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia
L. Roeker, D. Knorr, M. Pessin, L. Ramanathan +4 more
2020Leukemia93 citations Open access
Semantic Scholar
COVID-19 in patients with CLL: improved survival outcomes and update on management strategies
L. Roeker, T. Eyre, Meghan C. Thompson, N. Lamanna +48 more
2021Blood62 citations Open access
Semantic Scholar
Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen
Meghan C. Thompson, R. Harrup, Catherine C. Coombs, L. Roeker +34 more
2022Blood Advances53 citations Open access
Semantic Scholar
Interim analysis of ZUMA-5: A phase II study of axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL).
C. Jacobson, J. Chavez, A. Sehgal, B. William +16 more
202049 citations
Semantic Scholar
Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study
A. Zayac, A. Evens, A. Danilov, Stephen D. Smith +53 more
2021Haematologica38 citations Open access
Semantic Scholar
Long-Term Follow-up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)
S. Neelapu, J. Chavez, A. Sehgal, N. Epperla +20 more
2021Blood37 citations Open access
Semantic Scholar
Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma
M. Scordo, J. Flynn, M. Gonen, S. Devlin +18 more
2023Blood Advances33 citations Open access
Semantic Scholar
Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma
J. Westin, F. Locke, M. Dickinson, A. Ghobadi +23 more
2023Clinical Cancer Research32 citations Open access
Semantic Scholar
Outcomes in patients with aggressive B‐cell non‐Hodgkin lymphoma after intensive frontline treatment failure
E. Ayers, Shao-Ying Li, L. Medeiros, D. Bond +36 more
2020Cancer31 citations Open access
Semantic Scholar
Primary Analysis of ZUMA-7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma
F. Locke, D. Miklos, C. Jacobson, M. Perales +26 more
2021Blood26 citations Open access
Semantic Scholar
Toxicities and Outcomes of Acalabrutinib-Treated Patients with Chronic Lymphocytic Leukemia: A Retrospective Analysis of Real World Patients
M. Yazdy, A. Mato, L. Roeker, Umair Jarral +22 more
2019Blood26 citations Open access
Semantic Scholar
Phase 1/2 study of cirmtuzumab and ibrutinib in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL).
Hun Lee, M. Choi, T. Siddiqi, J. Barrientos +14 more
202123 citations
Semantic Scholar
Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study.
M. Shadman, B. Manzoor, K. Sail, H. Tuncer +27 more
2023Clinical Lymphoma, Myeloma & Leukemia20 citations Open access
Semantic Scholar
Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma: a prospective study
M. Donato, Steven Park, Melissa Baker, R. Korngold +44 more
2020medRxiv20 citations Open access
Semantic Scholar
Tafasitamab and Lenalidomide in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL): Real World Outcomes in a Multicenter Retrospective Study
D. Qualls, Michael J. Buege, Phuong H. Dao, P. Caimi +14 more
2022Blood19 citations Open access
Semantic Scholar
Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma
M. Donato, Steven Park, Melissa Baker, R. Korngold +44 more
2021JCI Insight19 citations Open access
Semantic Scholar
Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in Patients with CD30-Expressing Peripheral T-Cell Lymphomas
A. Herrera, J. Zain, K. Savage, T. Feldman +13 more
2021Blood18 citations Open access
Semantic Scholar
Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies
M. Davids, O. O'Connor, W. Jurczak, F. Samaniego +28 more
2021Blood Advances18 citations Open access
Semantic Scholar
Safety and Efficacy of Consolidation Therapy with Ipilimumab Plus Nivolumab after Autologous Stem Cell Transplantation.
A. Skarbnik, M. Donato, R. Feinman, S. Rowley +12 more
2020Transplantation and Cellular Therapy18 citations Open access
Semantic Scholar
Real-world Clinical Outcomes of First-Line Ibrutinib or Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia by Risk Status
Qing Huang, K. Deering, Q. Harshaw, L. Leslie
2022Advances in Therapy14 citations Open access
Semantic Scholar
Venetoclax Re-Treatment of Chronic Lymphocytic Leukemia (CLL) Patients after a Previous Venetoclax-Based Regimen
Meghan C. Thompson, J. Allan, K. Sail, B. Manzoor +22 more
202014 citations Open access
Semantic Scholar
Subcutaneous Epcoritamab in Combination with Rituximab + Lenalidomide (R2) for First-Line Treatment of Follicular Lymphoma: Initial Results from Phase 1/2 Trial
L. Falchi, L. Leslie, D. Belada, K. Kopeckova +20 more
2022Blood13 citations Open access
Semantic Scholar
Outcomes in ZUMA-5 with axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) who had the high-risk feature of progression within 24 months from initiation of first anti-CD20–containing chemoimmunotherapy (POD24).
C. Jacobson, J. Chavez, A. Sehgal, B. William +16 more
202113 citations
Semantic Scholar
Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-World Analysis
A. Zayac, A. Evens, A. Stadnik, Stephen D. Smith +48 more
2019Blood13 citations Open access
Semantic Scholar
Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase 2 Study of an MRD-driven Approach
L. Roeker, T. Feldman, J. Soumerai, V. Falco +22 more
2022Clinical Cancer Research11 citations Open access
Semantic Scholar
Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma
C. Ujjani, Catherine Lai, L. Leslie, P. Ramzi +21 more
2020Blood11 citations
Semantic Scholar
Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukemia
T. Eyre, N. Lamanna, L. Roeker, C. Ujjani +26 more
2020Haematologica11 citations Open access
Semantic Scholar
Umbralisib monotherapy demonstrates efficacy and safety in patients with relapsed/refractory marginal zone lymphoma: A multicenter, open label, registration directed phase II study.
N. Fowler, F. Samaniego, W. Jurczak, E. Lech-Maranda +16 more
2019Journal of Clinical Oncology11 citations
Semantic Scholar
A Rare Case of Grey Zone Lymphoma Successfully Treated with Brentuximab Vedotin and R-CHP Chemotherapy
R. Mallipudi, Lance Alquran, V. A. Shenoy, L. Leslie +1 more
2019Case Reports in Oncological Medicine11 citations Open access
Semantic Scholar
Safety and Efficacy Data for Combined Checkpoint Inhibition with Ipilimumab (Ipi) and Nivolumab (Nivo) As Consolidation Following Autologous Stem Cell Transplantation (ASCT) for High-Risk Hematological Malignancies — CPIT-001 Trial
A. Skarbnik, M. Donato, R. Korngold, R. Feinman +10 more
2018Blood11 citations
Semantic Scholar
Subcutaneous Epcoritamab with Rituximab + Lenalidomide in Patients with Relapsed or Refractory Follicular Lymphoma:Phase 1/2 Trial Update
L. Falchi, P. Abrisqueta, M. Nijland, S. Leppä +17 more
2022Blood10 citations Open access
Semantic Scholar
Umbralisib, the Once Daily Dual Inhibitor of PI3Kδ and Casein Kinase-1ε Demonstrates Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma: Results from the Phase 2 Global Unity-NHL Trial
P. Zinzani, F. Samaniego, W. Jurczak, N. Ghosh +24 more
202010 citations
Semantic Scholar
Safety, Pharmacokinetics and Activity of CA-4948, an IRAK4 Inhibitor, for Treatment of Patients with Relapsed or Refractory Hematologic Malignancies: Results from the Phase 1 Study
G. Nowakowski, L. Leslie, A. Younes, A. Rosenthal +7 more
2020Blood10 citations Open access
Semantic Scholar
Novel Therapies for Follicular Lymphoma and Other Indolent Non-Hodgkin Lymphomas
L. Leslie
2021Current Treatment Options in Oncology9 citations Open access
Semantic Scholar
UMBRALISIB MONOTHERAPY DEMONSTRATES EFFICACY AND SAFETY IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA: A MULTICENTER, OPEN‐LABEL, REGISTRATION DIRECTED PHASE 2 STUDY
P. Zinzani, F. Samaniego, Wojciech Jurczak, E. Lech-Maranda +18 more
2019Hematological Oncology8 citations
Semantic Scholar
Axicabtagene ciloleucel (axi-cel) in combination with rituximab (Rtx) for the treatment (Tx) of refractory large B-cell lymphoma (R-LBCL): Outcomes of the phase 2 ZUMA-14 study.
P. Strati, L. Leslie, P. Shiraz, L. Budde +11 more
2022Journal of Clinical Oncology7 citations
Semantic Scholar
Targeting indolent non-Hodgkin lymphoma
L. Leslie, A. Skarbnik, C. Bejot, S. Stives +2 more
2017Expert Review of Hematology7 citations
Semantic Scholar
Worldwide Examination of Patients with CLL Hospitalized for COVID-19
L. Roeker, L. Scarfò, T. Chatzikonstantinou, P. Abrisqueta +149 more
2020Blood6 citations Open access
Semantic Scholar
Improved Survival of Lymphoma Patients with COVID-19 in the Modern Treatment and Vaccination Era
A. Della Pia, Charles Zhao, Parul Jandir, Amolika Gupta +10 more
2022Cancers5 citations Open access
Semantic Scholar
A Phase 2 Study Evaluating the Addition of Ublituximab and Umbralisib (U2) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL): A Minimal Residual Disease (MRD)-Driven, Time-Limited Approach
L. Roeker, L. Leslie, J. Soumerai, V. Falco +17 more
2021Blood5 citations Open access
Semantic Scholar
Cirmtuzumab, an Anti-ROR1 Antibody, in Combination with Ibrutinib: Clinical Activity in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL) from a Phase 1/2 Study
Hun Lee, M. Choi, T. Siddiqi, W. Wierda +16 more
20205 citations
Semantic Scholar
Clinical Outcomes Among Real-World Patients with Chronic Lymphocytic Leukemia (CLL) Initiating First-Line Ibrutinib or Chemoimmunotherapy (CIT) Stratified By Risk Status: Results from a US Retrospective Chart Review Study
Qing Huang, K. Deering, Q. Harshaw, T. Bhagnani +1 more
20205 citations Open access
Semantic Scholar
COVID-19 Impact on Lymphoma Patients' Clinical Outcomes - an Observational Cohort Study
A. Ip, A. Mato, J. Intrator, Nicholas Howard +8 more
2020Blood5 citations Open access
Semantic Scholar
Outcomes among adult recipients of CD19 CAR T-cell therapy for Burkitt lymphoma.
Laura S. Samples, H. Sadrzadeh, M. Frigault, C. Jacobson +16 more
2023Journal of Clinical Oncology4 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

A. Mato×12
Invite
A. Mato — researcher profile on SciRah
T. Feldman×12
Invite
T. Feldman — researcher profile on SciRah
Olalekan O. Oluwole×11
Invite
Olalekan O. Oluwole — researcher profile on SciRah
J. Pagel×11
Invite
J. Pagel — researcher profile on SciRah

×11

Invite

J. Chavez — researcher profile on SciRah

Invite

L. Roeker — researcher profile on SciRah

C. Jacobson×10

Invite

C. Jacobson — researcher profile on SciRah

Invite

A. Goy — researcher profile on SciRah

Invite

N. Lamanna — researcher profile on SciRah

Invite

J. Allan — researcher profile on SciRah

Invite

M. Kamdar — researcher profile on SciRah

Invite

A. Skarbnik — researcher profile on SciRah